CRISPR Therapeutics AG
CRSP43.045USD
+1.465+3.52%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
3.72BCap. mercado
PérdidaP/E TTM
Más Datos de CRISPR Therapeutics AG Compañía
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Información de la empresa
Símbolo de cotizaciónCRSP
Nombre de la empresaCRISPR Therapeutics AG
Fecha de salida a bolsaOct 19, 2016
Fundada en2013
Director ejecutivoDr. Samarth Kulkarni, Ph.D.
Número de empleados393
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 19
DirecciónBaarerstrasse 14
CiudadZUG
Bolsa de valoresNASDAQ Global Market Consolidated
PaísSwitzerland
Código postal6300
Teléfono41415613279
Sitio Webhttps://crisprtx.com/
Símbolo de cotizaciónCRSP
Fecha de salida a bolsaOct 19, 2016
Fundada en2013
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
280.71K
+18.70%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Sandesh Mahatme
Mr. Sandesh Mahatme
Independent Director
Independent Director
--
--
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Fardis, Ph.D.
Dr. Maria Fardis, Ph.D.
Independent Director
Independent Director
--
--
Dr. H. Edward Fleming, Jr., M.D.
Dr. H. Edward Fleming, Jr., M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
280.71K
+18.70%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 20 de may
Actualizado: mar., 20 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
11.77%
Capital International Investors
7.03%
T. Rowe Price Investment Management, Inc.
4.40%
Nikko Asset Management Co., Ltd.
2.94%
Nikko Asset Management Americas, Inc.
2.94%
Other
70.92%
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
11.77%
Capital International Investors
7.03%
T. Rowe Price Investment Management, Inc.
4.40%
Nikko Asset Management Co., Ltd.
2.94%
Nikko Asset Management Americas, Inc.
2.94%
Other
70.92%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
41.25%
Investment Advisor/Hedge Fund
20.51%
Hedge Fund
5.55%
Research Firm
4.15%
Venture Capital
3.64%
Individual Investor
1.69%
Bank and Trust
0.73%
Sovereign Wealth Fund
0.51%
Pension Fund
0.39%
Other
21.57%
Participación institucional
Actualizado: lun., 24 de feb
Actualizado: lun., 24 de feb
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
934
69.16M
80.09%
-72.64K
2024Q4
955
68.20M
79.52%
-1.17M
2024Q3
962
64.14M
75.29%
-1.47M
2024Q2
976
63.22M
74.44%
-1.89M
2024Q1
986
62.72M
74.09%
+4.47M
2023Q4
985
55.14M
69.41%
-4.96M
2023Q3
992
55.19M
69.50%
-6.68M
2023Q2
1037
54.86M
69.51%
-8.28M
2023Q1
1053
55.90M
70.89%
-6.49M
2022Q4
1074
54.64M
69.81%
-8.49M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
ARK Investment Management LLC
8.97M
10.46%
-149.43K
-1.64%
Dec 31, 2024
Capital International Investors
8.74M
10.19%
+816.79K
+10.30%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
3.81M
4.44%
+1.07M
+39.24%
Dec 31, 2024
Nikko Asset Management Co., Ltd.
2.75M
3.2%
-222.36K
-7.49%
Dec 31, 2024
Nikko Asset Management Americas, Inc.
2.75M
3.2%
-221.54K
-7.47%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
2.51M
2.93%
+87.43K
+3.60%
Dec 31, 2024
State Street Global Advisors (US)
2.49M
2.9%
-501.46K
-16.75%
Dec 31, 2024
Fidelity Management & Research Company LLC
2.22M
2.59%
-152.87K
-6.43%
Dec 31, 2024
The Vanguard Group, Inc.
1.72M
2%
+8.83K
+0.52%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
ARK Genomic Revolution ETF
7.73%
ARK Innovation ETF
5.02%
Global X Genomics & Biotechnology ETF
3.5%
AXS Green Alpha ETF
3.22%
WisdomTree BioRevolution Fund
1.95%
Virtus LifeSci Biotech Products ETF
1.39%
SPDR S&P Biotech ETF
1.19%
Direxion Daily S&P Biotech Bull 3X Shares
0.78%
Main Thematic Innovation ETF
0.56%
Invesco Nasdaq Biotechnology ETF
0.33%
Ver más
ARK Genomic Revolution ETF
Proporción7.73%
ARK Innovation ETF
Proporción5.02%
Global X Genomics & Biotechnology ETF
Proporción3.5%
AXS Green Alpha ETF
Proporción3.22%
WisdomTree BioRevolution Fund
Proporción1.95%
Virtus LifeSci Biotech Products ETF
Proporción1.39%
SPDR S&P Biotech ETF
Proporción1.19%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.78%
Main Thematic Innovation ETF
Proporción0.56%
Invesco Nasdaq Biotechnology ETF
Proporción0.33%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
